Lilly’s Retevmo wins US nod for specific lung, thyroid cancers
The selective RET kinase inhibitor was cleared under the regulator’s accelerated approval process
Read More
Tag: LIBRETTO-001
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
